Revive Therapeutics Ltd.

RVVTFOTCHealthcare● Active

$0.03

+$0.00(+17.69%)

Market Cap$11074888

P/E Ratio—

52W High$0.059

52W Low$0.006

Avg Volume614K

Open$0.02

Beta-1.98

Revenue Financials Earnings

Revive Therapeutics Ltd. (RVVTF) Revenue

Annual & quarterly revenue history · segment & region breakdown

RVVTF · revenue · updated Jun 10, 2026

Core revenue metrics

Trailing 12 months

Revive Therapeutics Ltd. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue

$0.00B

4-quarter sum · USD

YoY growth

+0.00%

vs FY —

Price / sales

—

mktCap ÷ TTM rev

Revenue per day

—

Est. TTM ÷ 365

Revenue / employee

$0K

3 employees

—

5Y CAGR

—

Fiscal year end

Dec 31

Currency

USD · GAAP

Filing

10-K / 10-Q

Source: FMP · Revive Therapeutics Ltd. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

– · Annual

YoY revenue growth %

revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year end	Revenue	Change	Growth

RVVTF revenue by year · RVVTF revenue history · RVVTF annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Revive Therapeutics Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Revive Therapeutics Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Revive Therapeutics Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Price history Financial statements Forecast

Frequently asked questions

RVVTF revenue · 4 questions

RVVTF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

RVVTF revenueRVVTF annual revenuewhat is RVVTF revenueRVVTF TTM revenue

▸ Source: FMP · Revive Therapeutics Ltd. SEC filings · GAAP · Revive Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026